Page 17 - 第22屆新創事業獎得獎專輯
P. 17
EVA Select, in comparison to other technologies, 科技產業組 Tech Industry Category
represents a disruptive innovation with the
following core competencies: Future Prospects
・Applicable for over a hundred types of solid "Putting Patients First" is our fundamental
tumors. principle. Current cancer treatment relies
mainly on standard treatment protocols and
・Personalized screening for each cancer doctors' experience to determine the best
treatment regimen. course of treatment. However, Differences
among individuals result in diverse outcomes
・D oes not alter the current clinical cancer for each patient’s treatment. Our services
treatment procedures. provide doctors with a deeper understanding
of how treatment plans affect a patient’s
・Minimizes physical burden on patients through cancer cells. This tool empowers them to
a blood-based liquid biopsy approach. customize treatment strategies based on each
patient’s unique condition. This reduces the
・It offers a straightforward, time-saving, and likelihood of patients self-experimenting with
safe cancer drug screening platform. treatments and decreases the potential risks
and expenses linked to ineffective therapies.
・P revent unnecessary side effects by aligning the
correct treatment plans with the appropriate Cancer, an unavoidable aspect of human
patients. evolution, is something everyone prays will
not afflict them or their loved ones. Our
・A ddresses the shortcomings of current genetic ambition is to become the“Google map”of
and routine testing. cancer treatment, aiding cancer patients and
doctors in navigating the complex landscape
・Does not impose additional human resource of treatment options through drug sensitivity
burdens on the clinical side. profiling, thereby providing a roadmap to
exit the“cancer maze.” We will continue to
innovate and research, striving to realize our
vision of offering humanity a cancer-free future.
16
